Respiratory syncytial virus: Update on infection, treatment, and prevention

Current Infectious Disease Reports

Volumn 3, Issue 3, 2001, Pages 242-246

  Krilov, Leonard R ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

Bronchiolitis; Palivizumab; Respiratory Syncytial Virus; Respiratory Syncytial Virus Infection; Severe Respiratory Syncytial Virus

Indexed keywords

EID: 0000011611     PISSN: 15233847     EISSN: 15343146     Source Type: Journal    
DOI: 10.1007/s11908-001-0026-3     Document Type: Article

References (36)

1. Shay DK, Holman RC, Newman RD, et al.: Bronchiolitisassociated hospitalizations among US children, 1980–1996. JAMA 1999, 282:1440–1446.Recent analysis that updates available data on the magnitude of pediatric hospitalizations related to RSV disease.
2. Heilaman CA: Respiratory syncytial and parainfluenza viruses. J Infect Dis 1990, 161:402–406.
3. Walsh EE, McConnochie KM, Long CE, et al.: Severity of respiratory syncytial virus is related to virus strain. J Infect Dis 1997, 175:814–820.
4. Ogilvie MM, Vatheneo S, Radford M, et al.: Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981, 7:263–271.
5. Hall CB, Douglas RG Jr: Modes of transmission of respiratory syncytial virus. J Pediatr 1981, 99:100–103.
6. Nosocomial respiratory syncytial virus infections. N Engl J Med 1975, 293:1343–1346.
7. Meissner HC, Welliver RC, Chartrand SA, et al.: Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis wih respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J 1996, 15:1059–1068.
8. Hall CB, Powell KR, Schnabel KC, et al.: Risk of secondary bacterial infection in infants hospitalized with respiratory syncytial virus infection. J Pediatr 1988, 113:266–271.
9. Hall CB, Kopelman AE, Douglas RG, et al.: Neonatal respiratory syncytial virus infection. N Engl J Med 1979, 300:393–396.
10. Shaw KN, Bell LM, Sherman NH: Outpatient assessment of infants with bronchiolitis. Am J Dis Child 1991, 145:151–155.
11. Krilov LR, Lipson SM, Barone SR, et al.: Evaluation of a rapid diagnostic test for respiratory syncytial virus (RSV): potential for bedside diagnosis. Pediatrics 1994, 93:903–906.
12. Lipson S, Popiolek D, Hu QZ, et al.: Efficacy of Directigen RSV testing in patient management following admission from the pediatric emergency department. J Hosp Infect 1999, 41:323–329.
13. Navas L, Wang E, deCarvalho V, et al.: Improved outcome of respiratory syncytial virus in a high-risk hospitalized population of Canadian children. Pediatric Investigators Collaborative Network on Infections in Canada. J Pediatr 1992, 121:348–354.
14. Kattan M, Keens TG, Lapierre J-G, et al.: Pulmonary function abnormalities in symptom-free children after bronchiolitis. Pediatrics 1997, 59:683–688.
15. Pullan CR, Hey EN: Wheezing, asthma, and pulmonary dysfunction10 years after infection with respiratory syncytial virus in infancy. Br Med J 1982, 284:1665–1669.
16. Sims DH, Downham MA, Gardner PS, et al.: Study of children with a history of respiratory syncytial virus bronchiolitis in infancy. Br Med J 1978, 1:11–14.
17. Sigurs N, Bjarnason R, Sigurbergsson F, et al.: Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000, 161:1501–1507.Well-matched study demonstrating increased wheezing episodes for up to 10 years in children who developed RSV lower respiratory tract infection in infancy.
18. Kattan M: Epidemiologic evidence of increased airway reactivity in children with a history of bronchiolitis. J Pediatr 1999, 135:S8-S13.The association between RSV lower respiratory tract infection and subsequent wheezing is well established; however, the exact role of the virus in causing long-term airway changes is still under investigation.
19. Edell DS, Bruce E, Hale K, et al.: Reduced long-term respiratory morbidity after treatment of respiratory syncytial virus bronchiolitis with ribavirin in previously healthy infants: a preliminary report. Pediatr Pulmunol 1998, 25:154–158.
20. Rodriguez WJ, Arrobio J, Fink R, et al.: Prospective follow-up and pulmonary function from a placebo-controlled randomized trial of ribavirin therapy in respiratory syncytial virus bronchiolitis. Arch Pediatr Adolesc Med 1999, 153:469–474.
21. Krilov LR, Mandel FS, Barone SR, et al.: Follow-up of children with respiratory syncytial virus lower respiratory tract infection in 1986 and 1987: potential effect of ribavirin on long-term pulmonary function. The Bronchiolitis Study Group. Pediatr Infect Dis J 1997, 16:273–276.
22. Long CE, Voter KZ, Barker WH, et al.: Long term follow-up of children hospitalized with respiratory syncytial virus lower respiratory tract infection and randomly treated with ribavirin or placebo. Pediatr Infect Dis J 1997, 16:1023–1028.
23. Alaro AJ, Lewander WJ, Dennehy P, et al.: The efficacy of nebulized metaproterenol in wheezing infants and young children. Am J Dis Child 1992, 146:412–418.
24. Ho L, Collis G, Landau LI, et al.: Effect of salbutamol on oxygen saturation in bronchioilitis. Arch Dis Child 1991, 66:1061–1064.
25. Gadomski AM, Lichenstein R, Horton L, et al.: Efficacy of albuterol in the management of bronchiolitis. Pediatrics 1994, 93:907–912.
26. Menon K, Sutcliffe T, Klassen TP: A randomized trial comparing the efficacy of epinephrine with salbutamol in the treatment of acute bronchiolitis. J Pediatr 1995, 126:1004–1007.
27. Englund JA, Piedra PA, Ahn YM, et al.: High-dose, shortduration ribavirin aerosol therapy compared with standard ribavirin therapy in children with suspected respiratory syncytial virus infection. J Pediatr 1994, 125:635–641.
28. American Academy of Pediatrics: Report of the Committee on Infectious Diseases of the American Academy of Pediatrics. Respiratory Syncytial Virus. In Red Book 2000, edn 25. Elk Grove, IL:Medical Economics; 2000:483–487. Includes up-to-date overview of RSV disease, epidemiology, and infection control issues. Includes Committee on Infectious Diseases guidelines on treatment and prevention.
29. McColl MD, Corser RB, Bremner J, et al.: Respiratory syncytial infection in adult BMT recipients: effective therapy with short duration nebulised ribavirin. Bone Marrow Transplant 1998, 21:423–425.
30. The PREVENT Study Group: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchoulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997, 99:93–99.
31. Simoes EAF, Sondheimer HM, Top FH, et al.: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital heart disease. J Pediatr 1998, 133:492–499.
32. The Impact Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531–537.The major study demonstrating efficacy and safety of palivizumab for premature infants with or without underlying lung disease.
33. Joffe S, Ray GT, Escobar GJ, et al.: Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants. Pediatrics 1999, 104:419–427.
34. Marchetti A, Lau H, Magar R, et al.: Impact of palivizumab on expected costs of respiratory syncytial virus infection in preterm infants and infants: potential for savings. Clin Therap 1999, 21:752–766.The optimal candidates for RSV prophylaxis, especially in the 33- to 35-week gestation group, are still in flux. Attempts to assess costeffectiveness have not offered a definitive answer to date, as evidenced by the differing conclusions in the above two studies.
35. Malhotra A, Krilov LR: Influenza and respiratory syncytial virus: update on infection, management and prevention. Pediatr Clin North Am 2000, 47:353–372.
36. Hall CB: Prospects for a respiratory syncytial virus vaccine. Science 1994, 265:1393–1394.